UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1152-13
Program Prior Authorization/Notification
Medication Cosentyx® (secukinumab) prefilled syringe or Sensoready pen
P&T Approval Date 2/2015, 3/2016, 3/2017, 3/2018, 2/2019, 2/2020, 7/2020, 7/2021, 2/2022,
2/2023, 7/2023, 1/2024, 1/2025
Effective Date 4/1/2025
1. Background:
Cosentyx (secukinumab) is a human interleukin-17A antagonist indicated for the treatment of
moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic
therapy or phototherapy, active psoriatic arthritis (PsA) in patients 2 years of age and older, adults
with active ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA)
with objective signs of inflammation, active enthesitis-related arthritis (ERA) in patients 4 years of
age and older, and adults with moderate to severe hidradenitis (HS).
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Cosentyx will be approved based on both of the following criteria:
(1) Diagnosis of moderate to severe plaque psoriasis
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia
(certolizumab), Enbrel (etanercept), Ilumya (tildrakizumab), Olumiant
(baricitinib), Otezla (apremilast), Simponi (golimumab), Orencia (abatacept),
Rinvoq (upadacitinib), Siliq (brodalumab), Skyrizi (risankizumab), Sotyktu
(deucravacitinib), Stelara (ustekinumab), Taltz (ixekizumab), Tremfya
(guselkumab), Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Cosentyx will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Cosentyx therapy
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia
(certolizumab), Enbrel (etanercept), Ilumya (tildrakizumab), Olumiant
(baricitinib), Otezla (apremilast), Simponi (golimumab), Orencia (abatacept),
Rinvoq (upadacitinib), Siliq (brodalumab), Skyrizi (risankizumab), Sotyktu
(deucravacitinib), Stelara (ustekinumab), Taltz (ixekizumab), Tremfya
(guselkumab), Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
B. Psoriatic Arthritis
1. Initial Authorization
a. Cosentyx will be approved based on both of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia
(certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept),
Otezla (apremilast), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi
(risankizumab), Stelara (ustekinumab), Taltz (ixekizumab), Tremfya
(guselkumab), Xeljanz/Xeljanz XR (tofacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Cosentyx will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Cosentyx therapy
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia
(certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept),
Otezla (apremilast), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi
(risankizumab), Stelara (ustekinumab), Taltz (ixekizumab), Tremfya
(guselkumab), Xeljanz/Xeljanz XR (tofacitinib)]
Authorization will be issued for 12 months.
C. Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis
1. Initial Authorization
© 2025 UnitedHealthcare Services, Inc.
2
a. Cosentyx will be approved based on both of the following criteria:
(1) Diagnosis of active ankylosing spondylitis or active non-radiographic axial
spondyloarthritis
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia
(certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept),
Simponi (golimumab), Rinvoq (upadacitinib), Taltz (ixekizumab), Xeljanz
(tofacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Cosentyx will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Cosentyx therapy
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia
(certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept),
Simponi (golimumab), Rinvoq (upadacitinib), Taltz (ixekizumab), Xeljanz
(tofacitinib)]
Authorization will be issued for 12 months.
D. Enthesitis-Related Arthritis
1. Initial Authorization
a. Cosentyx will be approved based on both of the following criteria:
(1) Diagnosis of active enthesitis-related arthritis
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Cosentyx will be approved based on both of the following criteria:
© 2025 UnitedHealthcare Services, Inc.
3
(1) Documentation of positive clinical response to Cosentyx therapy
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
E. Hidradenitis Suppurativa (HS)
1. Initial Authorization
a. Cosentyx will be approved based on both of the following criteria:
(1) Diagnosis of moderate to severe hidradenitis suppurativa
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Cosentyx will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Cosentyx therapy.
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits and/or Step Therapy may be in place.
© 2025 UnitedHealthcare Services, Inc.
4
4. Reference:
1. Cosentyx [package insert]. East Hanover, NJ. Novartis Pharmaceuticals Corp.; October 2024.
Program Prior Authorization/Notification - Cosentyx (secukinumab)
Change Control
2/2015 New program.
3/2016 Annual review. Updated background information and clinical criteria to
include the two new indications for active psoriatic arthritis and active
ankylosing spondylitis. Added Otezla to the criteria for medications that
cannot be used in combination with Cosentyx for plaque psoriasis and
psoriatic arthritis. Updated reference.
3/2017 Annual review with no changes to criteria.
3/2018 Annual review with no changes to criteria. Updated reference.
2/2019 Annual review with no changes to criteria. Updated reference.
2/2020 Annual review with no changes to criteria. Updated reference.
7/2020 Updated background and criteria to include new indication for active
non-radiographic axial spondyloarthritis. Changed reauthorization
duration to 12 months. Updated reference.
7/2021 Annual review. Updated background to include expanded indication
for moderate to severe plaque psoriasis to pediatric patients 6 years and
older. Updated reference.
2/2022 Updated background and clinical criteria with new indication for ERA.
Updated reference.
2/2023 Annual review. Updated listed examples from Humira to adalimumab
and added Rinvoq. Added state mandate footnote.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
1/2024 Added coverage criteria for new indication for Hidradenitis Suppurativa
(HS). Updated background and reference.
1/2025 Annual review with no changes to clinical criteria. Updated examples
with no change to clinical intent. Updated reference.
© 2025 UnitedHealthcare Services, Inc.
5